NxThera, Inc., a Maple Grove, Minnesota-based medical device company developing endourology applications, completed a Series C round of financing.
The initial closing of this Series C round was reported in August of 2013 (read here).
This financing is being used to fund NxThera’s:
(i) Rezūm® U.S. pivotal clinical trial, the data from which will be used to seek FDA clearance to market its Rezūm System to treat benign prostatic hyperplasia (BPH),
(ii) commercialization of its Rezūm System to treat BPH at select centers in Europe, and
(iii) clinical feasibility studies to evaluate applications of Convective WAVE Technology to treat prostate cancer and kidney cancer.
Founded in 2008 and led by Bob Paulson, president and chief executive officer, NxThera applies its Convective WAVE Technology platform to treat a variety of endourology conditions including BPH, prostate cancer and kidney cancer. Its sterile water vapor technology platform enables the delivery of targeted BPH treatments in an office-based procedure to provide improvements in urine flow and improved quality of life.
FinSMEs
27/02/2014
Related News
17/03/2011: NxThera Completes $12.6M Series B Equity Financing